Research programme: pro-inflammatory gene regulators - Amgen
Alternative Names: NF-kappa-B signal transduction pathway inhibitors research programme - Amgen; Pro-inflammatory gene regulators research programme - Amgen; Research programme: NF-kappa-B signal transduction pathway inhibitors - AmgenLatest Information Update: 12 Apr 2007
At a glance
- Originator Amgen
- Class
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 12 Apr 2007 No development reported - Preclinical for Inflammation in USA (PO)
- 17 Aug 2004 Tularik has been acquired and merged into Amgen
- 12 Dec 2003 This programme is still in active development